Founded in 2001, Brooklyn Park-based medtech startup CVRx Inc. has raised hundreds of million of dollars in investor capital, but it hadn't been able to sell its heart-failure device in the U.S.
Until now.
CVRx announced late last week that the FDA had approved the Barostim Neo, CVRx's pacemaker-esque implantable device. It's been available in Europe for years.
The Barostim Neo uses neuromodulation therapy, which means it stimulates the nervous system by using an electrode placed on the neck's…
